STOCK TITAN

Mersana Therapeutics Inc SEC Filings

MRSN NASDAQ

Welcome to our dedicated page for Mersana Therapeutics SEC filings (Ticker: MRSN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing a 250-page biotech filing packed with pharmacology terms, trial endpoints, and collaboration clauses can slow any analysis. Mersana Therapeutics SEC documents layer complex antibody-drug conjugate science on top of detailed R&D accounting—an ideal recipe for missed insights.

Stock Titan fixes that friction. Our AI-powered summaries translate every Mersana Therapeutics annual report 10-K simplified section, spotlighting Fleximer platform updates, cash runway disclosures, and key risk factors. Need the latest Mersana Therapeutics quarterly earnings report 10-Q filing? We post it the moment EDGAR releases, then surface revenue from partnerships, clinical-trial spend by program, and any changes to liquidity outlook—no manual page-flipping required.

Looking for insider sentiment? Receive real-time alerts whenever a director files Mersana Therapeutics insider trading Form 4 transactions. Our dashboard groups Mersana Therapeutics executive stock transactions Form 4 by buyer, price, and trial milestone so you can track conviction without spreadsheets.

  • Rapid AI notes that flag 8-K material event triggers—perfect for "Mersana Therapeutics 8-K material events explained" searches.
  • Side-by-side redline of sequential 10-Qs to answer "Mersana Therapeutics earnings report filing analysis."
  • One-click access to the definitive proxy for "Mersana Therapeutics proxy statement executive compensation."

Whether you’re understanding Mersana Therapeutics SEC documents with AI for a quick model update or deep-diving into drug-candidate economics, Stock Titan delivers every filing type—10-K, 10-Q, 8-K, S-3, Form 4—along with plain-English context. Spend minutes, not evenings, turning dense ADC disclosures into actionable decisions.

Rhea-AI Summary

Mersana Therapeutics, Inc. (NASDAQ: MRSN) filed an 8-K to disclose the termination of its October 29, 2021 loan and security agreement with Oxford Finance LLC and other lenders. On July 1, 2025, the company paid approximately $17.9 million, which fully satisfied and discharged all outstanding indebtedness and related obligations under the agreement. As a result, the loan agreement and its related collateral security documents are no longer in effect.

The disclosure was made under Item 1.02 (“Termination of a Material Definitive Agreement”). No other material events, financial results, or operational updates were included in this filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Mersana Therapeutics (MRSN)?

The current stock price of Mersana Therapeutics (MRSN) is $0.3439 as of July 11, 2025.

What is the market cap of Mersana Therapeutics (MRSN)?

The market cap of Mersana Therapeutics (MRSN) is approximately 36.1M.

What is the primary focus of Mersana Therapeutics?

Mersana Therapeutics focuses on the development of antibody-drug conjugates (ADCs) for cancer treatment, leveraging a proprietary Fleximer platform to design targeted therapies.

How does the Fleximer platform benefit their ADC development?

The Fleximer platform allows for the custom design of ADCs, enabling precise control over payload release, improved tumor targeting, and reduced systemic side effects compared to conventional ADC approaches.

What are the two core ADC platforms used by Mersana?

Mersana utilizes the Dolasynthen platform, which delivers proprietary auristatin payloads, and the Immunosynthen platform, which delivers STING agonist payloads to stimulate an immune response.

What therapeutic areas does Mersana target?

The company's therapies are primarily targeted at various cancers, especially those with high unmet medical needs, by delivering potent anti-tumor agents directly to cancer cells.

How does Mersana differentiate itself in the ADC market?

Mersana differentiates itself through its flexible and precise drug design, which allows for increased payload delivery and reduced toxicity, addressing challenges common to traditional ADCs.

What role do strategic collaborations play in Mersana's business model?

Collaborations with major pharmaceutical companies are key to Mersana’s strategy, providing resources, expertise, and accelerated pathways for clinical development and commercialization of their ADC candidates.

How does Mersana ensure clinical excellence in its therapies?

The company follows rigorous scientific methods and transparent clinical trial designs, continuously investing in research and development to ensure that its therapies meet significant clinical needs with a strong safety and efficacy profile.

What are some common industry keywords associated with Mersana?

Common industry keywords include ADC, immunoconjugate, targeted therapy, and precision oncology, all of which highlight the company's focus on innovative cancer treatments.
Mersana Therapeutics Inc

NASDAQ:MRSN

MRSN Rankings

MRSN Stock Data

36.08M
122.65M
1.4%
85.51%
8.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE